You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/7269
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde Matos, Djamile Cordeiro-
dc.contributor.authorAbreu de Ribeiro, Livia Carolina-
dc.contributor.authorTansini, Aline-
dc.contributor.authorFerreira, Lucas Souza-
dc.contributor.authorPolesi Placeres, Marisa Campos-
dc.contributor.authorLuis Colombo, Lucas-
dc.contributor.authorCarlos, Iracilda Zeppone-
dc.date.accessioned2014-05-20T13:23:52Z-
dc.date.available2014-05-20T13:23:52Z-
dc.date.issued2012-07-24-
dc.identifierhttp://dx.doi.org/10.1186/1472-6882-12-107-
dc.identifier.citationBmc Complementary and Alternative Medicine. London: Biomed Central Ltd., v. 12, p. 6, 2012.-
dc.identifier.issn1472-6882-
dc.identifier.urihttp://hdl.handle.net/11449/7269-
dc.description.abstractBackground: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer.Methods: The percentage of dendritic cells and CD4(+) and CD8(+) T cells in the spleen (flow cytometry), cytokines' release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 mu g/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test.Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-gamma and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-beta levels were decreased. There was also an increase in macrophage's activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively).Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
dc.format.extent6-
dc.language.isoeng-
dc.publisherBiomed Central Ltd.-
dc.sourceWeb of Science-
dc.subjectPulchellinen
dc.subjectBreast canceren
dc.subjectCytokinesen
dc.subjectImmune systemen
dc.titleImmunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatmenten
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniv Buenos Aires-
dc.description.affiliationSão Paulo State Univ, Clin Immunol Lab, Sch Pharmaceut Sci, São Paulo, Brazil-
dc.description.affiliationUniv Buenos Aires, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina-
dc.description.affiliationUniv Estadual Paulista, Fac Ciencias Farmaceut, BR-14801902 Araraquara, SP, Brazil-
dc.description.affiliationUnespSão Paulo State Univ, Clin Immunol Lab, Sch Pharmaceut Sci, São Paulo, Brazil-
dc.description.affiliationUnespUniv Estadual Paulista, Fac Ciencias Farmaceut, BR-14801902 Araraquara, SP, Brazil-
dc.identifier.doi10.1186/1472-6882-12-107-
dc.identifier.wosWOS:000310323800001-
dc.rights.accessRightsAcesso aberto-
dc.identifier.fileWOS000310323800001.pdf-
dc.relation.ispartofBMC Complementary and Alternative Medicine-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.